Literature DB >> 18949417

Heat shock protein 27, a novel regulator of 5-fluorouracil resistance in colon cancer.

Masashi Tsuruta1, Hideki Nishibori, Hirotoshi Hasegawa, Yoshiyuki Ishii, Takashi Endo, Tetsuro Kubota, Masaki Kitajima, Yuko Kitagawa.   

Abstract

The resistance of colon cancer to 5-fluorouracil (5-FU) is a critical issue, and the cause of this resistance cannot always be explained based on the known molecules. Heat shock protein 27 (HSP27) mRNA expression has recently been shown to be correlated with 5-FU resistance in 5-FU-resistant cell lines. In this study, we attempted to elucidate the functional mechanism of HSP27 in 5-FU resistance in colon cancer. HSP27 protein levels in several human colon cancer cell lines (LoVo, HCT15, WiDr, HCT116, HT-29 and SW480) were determined by immunoblot and densitometry analysis. The in vitro growth inhibition rates (IR) of the cell lines at various concentrations of 5-FU were assessed by MTT assay. The degree of 5-FU resistance was estimated as the drug concentration inducing 50% IR (IC50). The HSP27 protein level and IC50 were significantly correlated in these cell lines (p=0.010). The effect of HSP27 overexpression on IC50 was evaluated in LoVo cells. HSP27 transfectants significantly increased IC50 and reduced HSP27 resistance. The effect of HSP27 down-regulation by HSP27 siRNA on IC50 was confirmed in HCT15 cells. HSP27 siRNA suppressed HSP27 protein levels and reduced IC50 in a dose-dependent manner. These data indicated that HSP27 is closely connected with 5-FU resistance in colon cancer and suggested that HSP27 levels predicted 5-FU resistance. HSP27 down-regulation overcame 5-FU resistance and HSP27 may be a clinical target in patients with 5-FU-resistant colon cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18949417

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  11 in total

1.  High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer.

Authors:  Karina Bauer; Ulrich Nitsche; Julia Slotta-Huspenina; Enken Drecoll; Claus Hann von Weyhern; Robert Rosenberg; Heinz Höfler; Rupert Langer
Journal:  Cell Oncol (Dordr)       Date:  2012-04-26       Impact factor: 6.730

Review 2.  Ins and Outs of Heat Shock Proteins in Colorectal Carcinoma: Its Role in Carcinogenesis and Therapeutic Perspectives.

Authors:  Batoul Abi Zamer; Waseem El-Huneidi; Mohamed Ahmed Eladl; Jibran Sualeh Muhammad
Journal:  Cells       Date:  2021-10-24       Impact factor: 6.600

3.  Inhibition of protein phosphorylation in MIA pancreatic cancer cells: confluence of metabolic and signaling pathways.

Authors:  Hengwei Zhang; Rui Cao; Wai-Nang Paul Lee; Caishu Deng; Yingchun Zhao; Joan Lappe; Robert Recker; Yun Yen; Qi Wang; Ming-Ying Tsai; Vay Liang Go; Gary Guishan Xiao
Journal:  J Proteome Res       Date:  2010-02-05       Impact factor: 4.466

4.  Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo.

Authors:  B Gibert; B Eckel; V Gonin; D Goldschneider; J Fombonne; B Deux; P Mehlen; A-P Arrigo; P Clézardin; C Diaz-Latoud
Journal:  Br J Cancer       Date:  2012-05-24       Impact factor: 7.640

5.  Ginkgo biloba extract decreases non-small cell lung cancer cell migration by downregulating metastasis-associated factor heat-shock protein 27.

Authors:  Jong-Rung Tsai; Po-Len Liu; Yung-Hsiang Chen; Shah-Hwa Chou; Ming-Chan Yang; Yu-Jen Cheng; Jhi-Jhu Hwang; Wei-Hsian Yin; Inn-Wen Chong
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

6.  Inhibition of heat shock protein 27 phosphorylation promotes sensitivity to 5-fluorouracil in colorectal cancer cells.

Authors:  Atsushi Matsunaga; Yoshiyuki Ishii; Masashi Tsuruta; Koji Okabayashi; Hirotoshi Hasegawa; Yuko Kitagawa
Journal:  Oncol Lett       Date:  2014-10-01       Impact factor: 2.967

7.  Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study.

Authors:  Cornelia Schuster; Lars A Akslen; Oddbjørn Straume
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

8.  Re-examining HSPC1 inhibitors.

Authors:  Sheah Lin Lee; Nina Claire Dempsey-Hibbert; Dale Vimalachandran; Terence David Wardle; Paul A Sutton; John H H Williams
Journal:  Cell Stress Chaperones       Date:  2017-03-02       Impact factor: 3.667

9.  Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement.

Authors:  C S Foster; A R Dodson; L Ambroisine; G Fisher; H Møller; J Clark; G Attard; J De-Bono; P Scardino; V E Reuter; C S Cooper; D M Berney; J Cuzick
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

10.  HSP27 and 70 expression in thymic epithelial tumors and benign thymic alterations: diagnostic, prognostic and physiologic implications.

Authors:  S Janik; A I Schiefer; C Bekos; P Hacker; T Haider; J Moser; W Klepetko; L Müllauer; H J Ankersmit; B Moser
Journal:  Sci Rep       Date:  2016-04-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.